Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development.

Sibilia M, Fleischmann A, Behrens A, Stingl L, Carroll J, Watt FM, Schlessinger J, Wagner EF.

Cell. 2000 Jul 21;102(2):211-20.

2.

A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis.

Casanova ML, Larcher F, Casanova B, Murillas R, Fernández-Aceñero MJ, Villanueva C, Martínez-Palacio J, Ullrich A, Conti CJ, Jorcano JL.

Cancer Res. 2002 Jun 15;62(12):3402-7.

3.

Transient activation of EGFR/AKT cell survival pathway and expression of survivin contribute to reduced sensitivity of human melanoma cells to betulinic acid.

Qiu L, Wang Q, Di W, Jiang Q, Schefeller E, Derby S, Wanebo H, Yan B, Wan Y.

Int J Oncol. 2005 Sep;27(3):823-30.

PMID:
16077934
4.

Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.

Rusyn EV, Reynolds ER, Shao H, Grana TM, Chan TO, Andres DA, Cox AD.

Oncogene. 2000 Sep 28;19(41):4685-94.

5.

CCAAT/enhancer binding protein-beta is a mediator of keratinocyte survival and skin tumorigenesis involving oncogenic Ras signaling.

Zhu S, Yoon K, Sterneck E, Johnson PF, Smart RC.

Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):207-12. Epub 2001 Dec 26.

6.
8.

In vivo cooperation between Bcl-xL and the phosphoinositide 3-kinase-Akt signaling pathway for the protection of epidermal keratinocytes from apoptosis.

Umeda J, Sano S, Kogawa K, Motoyama N, Yoshikawa K, Itami S, Kondoh G, Watanabe T, Takeda J.

FASEB J. 2003 Apr;17(6):610-20.

PMID:
12665473
9.

Activation of the epidermal growth factor receptor signal transduction pathway stimulates tyrosine phosphorylation of protein kinase C delta.

Denning MF, Dlugosz AA, Threadgill DW, Magnuson T, Yuspa SH.

J Biol Chem. 1996 Mar 8;271(10):5325-31.

10.
11.
12.

Ultraviolet irradiation activates PI 3-kinase/AKT survival pathway via EGF receptors in human skin in vivo.

Wan YS, Wang ZQ, Shao Y, Voorhees JJ, Fisher GJ.

Int J Oncol. 2001 Mar;18(3):461-6.

PMID:
11179472
13.

H2O2-induced transactivation of EGF receptor requires Src and mediates ERK1/2, but not Akt, activation in renal cells.

Zhuang S, Schnellmann RG.

Am J Physiol Renal Physiol. 2004 May;286(5):F858-65. Epub 2004 Feb 10. Erratum in: Am J Physiol Renal Physiol. 2004 Oct;56(4):F857. Zhougang, Shougang [corrected to Zhuang, Shougang].

14.
15.

Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation.

Younes MN, Yigitbasi OG, Park YW, Kim SJ, Jasser SA, Hawthorne VS, Yazici YD, Mandal M, Bekele BN, Bucana CD, Fidler IJ, Myers JN.

Cancer Res. 2005 Jun 1;65(11):4716-27.

16.
17.

Epidermal growth factor receptor down-regulation induced by UVA in human keratinocytes does not require the receptor kinase activity.

He YY, Huang JL, Gentry JB, Chignell CF.

J Biol Chem. 2003 Oct 24;278(43):42457-65. Epub 2003 Aug 20.

18.

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.

Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL.

Oncogene. 2002 Sep 12;21(41):6255-63.

19.

Bradykinin-induced p42/p44 MAPK phosphorylation and cell proliferation via Src, EGF receptors, and PI3-K/Akt in vascular smooth muscle cells.

Yang CM, Lin MI, Hsieh HL, Sun CC, Ma YH, Hsiao LD.

J Cell Physiol. 2005 Jun;203(3):538-46.

PMID:
15573401

Supplemental Content

Support Center